Therefore, potential antigen downregulation or loss (which is commonly seen with CD19 CAR) can render CAR-T cells ineffective unless multiple antigens are targeted, which is challenging in the limited antigenic repertoire of AML [56]. The gene discussed is CD19; the disease is acute myeloid leukemia.